NASDAQ:LEXX Lexaria Bioscience Q4 2026 Earnings Date & Estimates $4.03 -0.46 (-10.24%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$4.09 +0.06 (+1.56%) As of 11/20/2026 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Lexaria Bioscience is estimated to report Q4 2026 earnings on Tuesday, November 24, 2026. The conference call is scheduled for 12:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ4 2026Announcement DateNovember 24, 2026Conference Call12:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Lexaria Bioscience in Q4 2026Lexaria Bioscience is expected to post earnings of -$0.90 per share on revenue of $50 thousand. Lexaria Bioscience last reported on July 13, 2026, posting -$0.08 per share and missing the -$0.06 consensus estimate. Lexaria Bioscience has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.90Expected Revenue$50 thousandRecent Track RecordLast ReportedQ3 2026Last Quarter EPS-$0.08 (Missed by -$0.02)EPS Beat Rate3 of last 8 quartersPrepare for the Q4 2026 CallEarnings HistoryCompany ProfileQ3 2026 Earnings ReportQ2 2026 Earnings ReportQ1 2026 Earnings Report Lexaria Bioscience Q4 2026 Earnings FAQ When does Lexaria Bioscience report Q4 2026 earnings? Lexaria Bioscience (NASDAQ:LEXX) is estimated to report Q4 2026 earnings on Tuesday, November 24, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Lexaria Bioscience's Q4 2026 earnings call? Lexaria Bioscience's Q4 2026 earnings conference call is scheduled for Tuesday, November 24, 2026 at 12:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Lexaria Bioscience? Analysts expect Lexaria Bioscience to post earnings of -$0.90 per share for Q4 2026. How much revenue is Lexaria Bioscience expected to report? The consensus revenue estimate for Lexaria Bioscience is $50 thousand for Q4 2026. Lexaria Bioscience Earnings HeadlinesLexaria Bioscience (LEXX) Projected to Release Earnings on TuesdayNovember 17, 2026 | americanbankingnews.comLexaria Bioscience Corp.: Lexaria Celebrates its 70th Patent AwardOctober 28, 2026 | finanznachrichten.dePrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.November 21 at 1:00 AM | Base Camp Trading (Ad)Lexaria Bioscience Corp.: Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross ProceedsSeptember 9, 2026 | finanznachrichten.deLEXX: Introducing DehydraTECH 3.0September 8, 2026 | finance.yahoo.comLexaria Bioscience advances 12% on Australian tax rebateSeptember 1, 2026 | seekingalpha.comSee More Lexaria Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lexaria Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexaria Bioscience and other key companies, straight to your email. Email Address About Lexaria BioscienceLexaria Bioscience (NASDAQ:LEXX) is a biotechnology company developing DehydraTECH, a patented technology designed to improve the delivery and absorption of orally administered drugs and other active compounds. The platform incorporates active ingredients into a lipid-based formulation and is being studied for its potential to affect absorption and delivery characteristics. The company’s research has explored applications in areas including hypertension, diabetes and weight management, epilepsy, and antiviral treatments. These programs are investigational; Lexaria’s work includes laboratory and clinical research rather than a broad portfolio of approved medicines. Based in British Columbia, Canada, Lexaria focuses on developing and licensing its delivery technology and advancing research with pharmaceutical ingredients. The company has also developed consumer products in the past, including hemp-derived products, but its current activities center on DehydraTECH research and development.View Lexaria Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestOwens Corning's Stock Slump May Have a Silver Lining for Dividend InvestorsThe Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity StocksHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to Run Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.